[CAS NO. 1357349-91-7] SPP-86
PRODUCTS SPECIFICATIONS [1357349-91-7]
DESCRIPTION [1357349-91-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 277.32 |
| Molecular Formula | C16H15N5 |
| SMILES | CC(C)N1C2=NC=NC(N)=C2C(C#CC3=CC=CC=C3)=N1 |
Summary
IC50 & Target
IC50: 8 nM (RET) [1] .
In Vitro
SPP86 (0-10 μM) inhibits MAPK signaling and proliferation in RET/PTC1 expressing TPC1 but not 8505C or C643 cells
[1]
.
SPP86 (0-10 μM) inhibits RET- induced phosphatidylinositide 3-kinases (PI3K)/Akt and MAPK signaling and estrogen receptorα (ERα) phosphorylation in MCF7 cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
| Cell Line: | Thyroid cancer derived cell lines expressing the RET/PTC1 rearrangement (TPC1), BRAF V600E (8505C) or RAS G13R (C643) mutations. |
| Concentration: | 0-10 μM. |
| Incubation Time: | 90 min. |
| Result: | Inhibited RET- induced ERK1/2 phosphorylation in thyroid cancer cell lines. |
Western Blot Analysis [1]
| Cell Line: | MCF7 cells (human breast cancer). |
| Concentration: | 0-10 μM. |
| Incubation Time: | 30 min. |
| Result: | Inhibited RET- induced ERα phosphorylation and proliferation in MCF7 cells. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 360.59 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.6059 mL | 18.0297 mL | 36.0594 mL |
| 5 mM | 0.7212 mL | 3.6059 mL | 7.2119 mL |
| 10 mM | 0.3606 mL | 1.8030 mL | 3.6059 mL |